KYTX Collar Strategy
KYTX (Kyverna Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019.
KYTX (Kyverna Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $472.1M, a beta of 2.06 versus the broader market, a 52-week range of 2.06-13.67, average daily share volume of 851K, a public-listing history dating back to 2024, approximately 112 full-time employees. These structural characteristics shape how KYTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.06 indicates KYTX has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a collar on KYTX?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current KYTX snapshot
As of May 13, 2026, spot at $10.66, ATM IV 68.50%, IV rank 5.12%, expected move 19.64%. The collar on KYTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 36-day expiry.
Why this collar structure on KYTX specifically: IV regime affects collar pricing on both sides; compressed KYTX IV at 68.50% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 19.64% (roughly $2.09 on the underlying). The 36-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KYTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on KYTX should anchor to the underlying notional of $10.66 per share and to the trader's directional view on KYTX stock.
KYTX collar setup
The KYTX collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KYTX near $10.66, the first option leg uses a $11.19 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KYTX chain at a 36-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KYTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $10.66 | long |
| Sell 1 | Call | $11.19 | N/A |
| Buy 1 | Put | $10.13 | N/A |
KYTX collar risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
KYTX collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on KYTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use collar on KYTX
Collars on KYTX hedge an existing long KYTX stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
KYTX thesis for this collar
The market-implied 1-standard-deviation range for KYTX extends from approximately $8.57 on the downside to $12.75 on the upside. A KYTX collar hedges an existing long KYTX position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current KYTX IV rank near 5.12% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on KYTX at 68.50%. As a Healthcare name, KYTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KYTX-specific events.
KYTX collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KYTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KYTX alongside the broader basket even when KYTX-specific fundamentals are unchanged. Always rebuild the position from current KYTX chain quotes before placing a trade.
Frequently asked questions
- What is a collar on KYTX?
- A collar on KYTX is the collar strategy applied to KYTX (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With KYTX stock trading near $10.66, the strikes shown on this page are snapped to the nearest listed KYTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are KYTX collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the KYTX collar priced from the end-of-day chain at a 30-day expiry (ATM IV 68.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a KYTX collar?
- The breakeven for the KYTX collar priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KYTX market-implied 1-standard-deviation expected move is approximately 19.64%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on KYTX?
- Collars on KYTX hedge an existing long KYTX stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current KYTX implied volatility affect this collar?
- KYTX ATM IV is at 68.50% with IV rank near 5.12%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.